Virtus LifeSci Biotech Clinical Trials ETF Rating $24.57 -0.68 (-2.69%) As of 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsRatingsShort InterestBuy This Stock Virtus LifeSci Biotech Clinical Trials ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BBC Aggregate RatingModerate Buy 2.92Holdings in BBC have an aggregate rating of Moderate Buy based on 188 analyst ratings issued in the past year covering 25 companies (33.4% of the portfolio).BBC Aggregate Price Target$24.57High Prediction$24.57Average Prediction$24.57Low Prediction$24.57Holdings in BBC have an aggregate price target of $24.57 and a range of $24.57 to $24.57 covering 25 companies (33.4% of the portfolio).BBC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy16 Buy rating(s)Moderate Buy7 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Virtus LifeSci Biotech Clinical Trials ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 BBC Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings3.23%CELCCelcuity$51.88-5.7%1.4183 of 5 stars3.00$56.50 8.9%41.76%MLYSMineralys Therapeutics$39.27-1.5%2.5149 of 5 stars2.83$43.50 10.8%6Insider TradeGap Down1.69%TRMLTourmaline Bio$47.73+0.1%0.8692 of 5 stars2.10$45.65 -4.4%101.47%RAPPRapport Therapeutics$26.36-3.6%3.1171 of 5 stars3.25$35.33 34.0%4Analyst ForecastInsider Trade1.43%STOKStoke Therapeutics$22.90-2.6%3.8433 of 5 stars3.22$25.57 11.7%9High Trading Volume1.39%OLMAOlema Pharmaceuticals$8.17-4.0%2.8044 of 5 stars2.83$24.00 193.8%6Positive News1.39%DNTHDianthus Therapeutics$36.75-5.5%2.9624 of 5 stars3.00$61.57 67.5%91.34%TERNTerns Pharmaceuticals$7.53-7.9%3.9866 of 5 stars2.67$15.49 105.7%6News CoveragePositive NewsAnalyst Forecast1.33%CNTACentessa Pharmaceuticals$22.79-0.8%3.2303 of 5 stars3.10$32.38 42.1%10Insider Trade1.32%LQDALiquidia Technologies$23.78-3.6%3.8578 of 5 stars3.00$32.11 35.0%10Insider TradeHigh Trading Volume1.31%NUVBNuvation Bio$3.21+1.3%3.1847 of 5 stars3.17$7.50 133.6%6News CoverageAnalyst Forecast1.29%MAZEMaze Therapeutics$22.94-2.3%3.5062 of 5 stars3.25$32.67 42.4%8Analyst ForecastInsider TradeHigh Trading Volume1.29%ARWRArrowhead Pharmaceuticals$30.69-2.6%4.2111 of 5 stars3.00$43.14 40.6%8Insider TradeAnalyst Revision1.25%COGTCogent Biosciences$11.97-5.9%2.8474 of 5 stars2.92$20.00 67.1%12Positive NewsHigh Trading Volume1.23%XERSXeris Biopharma$7.72-7.0%2.6475 of 5 stars2.83$7.08 -8.2%6High Trading Volume1.18%PRTAProthena$8.07-1.3%3.6884 of 5 stars2.33$19.75 144.7%91.14%CYTKCytokinetics$48.66-1.3%4.2652 of 5 stars2.87$75.38 54.9%15Trending News1.12%SVRASavara$3.53-1.9%3.043 of 5 stars2.83$7.50 112.5%6Trending NewsHigh Trading Volume1.10%UPBUpstream Bio$16.38-5.2%1.5322 of 5 stars3.00$56.50 244.9%4High Trading Volume1.08%SNDXSyndax Pharmaceuticals$14.78-4.3%3.7721 of 5 stars3.00$39.22 165.4%10Analyst Forecast1.06%EYPTEyepoint Pharmaceuticals$13.25-3.7%1.741 of 5 stars3.00$26.86 102.7%7Positive NewsHigh Trading Volume1.03%ABCLAbCellera Biologics$4.51-4.4%3.0353 of 5 stars3.00$8.00 77.4%61.01%ARCTArcturus Therapeutics$20.46+4.3%3.0426 of 5 stars3.00$50.57 147.2%8Positive NewsHigh Trading Volume1.01%CRVSCorvus Pharmaceuticals$5.87-4.1%1.7632 of 5 stars3.00$13.00 121.5%3Positive NewsHigh Trading Volume0.99%SIONSionna Therapeutics$23.14-0.4%2.898 of 5 stars3.00$38.00 64.2%6High Trading Volume This page (NYSEARCA:BBC) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
